Get the Stockscreener App
83.09
0.64%
0.53
After Hours:
83.46
0.37
+0.45%
Glaukos Corporation stock is traded at $83.09, with a volume of 718.99K.
It is up +0.64% in the last 24 hours and up +0.40% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$82.56
Open:
$83.58
24h Volume:
718.99K
Relative Volume:
0.79
Market Cap:
$4.77B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-28.07
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-4.08%
1M Performance:
+0.40%
6M Performance:
-7.75%
1Y Performance:
-34.52%
1-Day Range:
$82.19
$84.70
1-Week Range:
$82.19
$87.83
52-Week Range:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
83.09 | 4.73B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Does Glaukos Corporation qualify in momentum factor screening2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
What to do if you’re stuck in Glaukos Corporation2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Can Glaukos Corporation hit a new high this monthGold Moves & Safe Entry Zone Tips - newser.com
Will Glaukos Corporation stock attract long term capital inflowsQuarterly Profit Summary & Detailed Earnings Play Strategies - newser.com
How to build a custom watchlist for Glaukos Corporation2025 Big Picture & Low Risk Entry Point Tips - newser.com
Glaukos (GKOS) Analyst Rating Update: BTIG Lowers Price Target | - GuruFocus
Is Glaukos Corporation stock dividend yield sustainable2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Combining machine learning predictions for Glaukos CorporationJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
How to read the order book for Glaukos CorporationWeekly Profit Summary & Community Verified Watchlist Alerts - newser.com
Using Python tools to backtest Glaukos Corporation strategiesJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Glaukos gains as Goldman Sachs initiates at Buy on valuation - MSN
InvestingPro’s January Glaukos warning preceded 47% stock drop By Investing.com - Investing.com Australia
Glaukos Corporation stock trend outlook and recovery pathQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Will Glaukos Corporation stock outperform energy sector in 20252025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
How hedge fund analytics apply to Glaukos Corporation stockPrice Action & Advanced Swing Trade Entry Plans - newser.com
Glaukos Corporation (NYSE:GKOS) Shares Could Be 46% Below Their Intrinsic Value Estimate - 富途牛牛
Analyzing net buyer seller activity in Glaukos Corporation2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Glaukos' (GKOS) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Glaukos breaks ground on high-tech facility in Alabama, eyes 150 jobs - Alabama News Center
Stifel maintains Buy rating on Glaukos stock ahead of Epioxa PDUFA date - Investing.com Nigeria
Stifel maintains Buy rating on Glaukos stock ahead of Epioxa PDUFA date By Investing.com - Investing.com South Africa
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 - The Globe and Mail
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Citigroup Issues Pessimistic Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
GKOS: Citigroup Lowers Price Target, Maintains Buy Rating | GKOS Stock News - GuruFocus
Glaukos breaks ground on high-tech facility in Huntsville, eyes 150 jobs - Alabama Department of Commerce
Volume spikes in Glaukos Corporation stock – what they meanQuarterly Portfolio Summary & High Accuracy Buy Signal Tips - newser.com
Is Glaukos Corporation stock bottoming outJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
Glaukos (GKOS): Valuation Spotlight as Goldman Sachs Highlights Pharma Growth Pivot and Innovative Pipeline - simplywall.st
Will Glaukos Corporation benefit from macro trends2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Quantitative breakdown of Glaukos Corporation recent moveMarket Activity Recap & Real-Time Volume Analysis - newser.com
Detecting support and resistance levels for Glaukos CorporationJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Published on: 2025-10-05 05:39:03 - newser.com
Will Glaukos Corporation stock maintain growth story2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
Why Glaukos Corporation (6GJ) stock is trending on social mediaQuarterly Portfolio Review & Safe Swing Trade Setups - newser.com
What macro factors could drive Glaukos Corporation (6GJ) stock higherEarnings Miss & Daily Profit Focused Stock Screening - newser.com
Using Bollinger Bands to evaluate Glaukos CorporationQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Is Glaukos Corporation stock a fit for income portfoliosJuly 2025 Intraday Action & Short-Term Trading Alerts - newser.com
Glaukos (NYSE:GKOS) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Is Glaukos Corporation (6GJ) stock positioned for digital growth eraJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
What makes Glaukos Corporation stock attractive to growth fundsJuly 2025 Pullbacks & High Accuracy Investment Signals - newser.com
Published on: 2025-10-03 05:01:41 - newser.com
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):